ANA PLUS Blot – Advanced Diagnostics of Systemic Autoimmune Diseases

Autoimmune diseases often develop gradually and present with a wide variety of clinical manifestations, making timely diagnosis a challenge. Patients frequently report fatigue, joint and muscle pain, skin changes, Raynaud's phenomenon, or dry eyes and mouth before a specific condition is identified.

In such cases, laboratory diagnostics play a crucial role. ANA PLUS Blot is a modern method designed to detect a broad spectrum of autoantibodies associated with various systemic autoimmune diseases.

What is ANA PLUS Blot?

ANA PLUS Blot is an immunoassay intended for the detection of a comprehensive panel of specific antinuclear and extractable nuclear antigen (ENA) antibodies in serum. The method complements standard ANA screening by enabling a more precise characterization of the patient's autoantibody profile.

Advantages of the Method

ANA PLUS Blot allows the simultaneous detection of multiple clinically significant autoantibodies in a single test. This provides:

• Faster diagnostic orientation
• Improved differential diagnosis between similar conditions
• Support in assessing the risk of developing specific autoimmune diseases
• Monitoring of patients with already established autoimmune disorders

Software-Assisted Interpretation with Clinical Guidance

The advanced result analysis platform provides not only automated evaluation of detected antibodies but also software-assisted interpretation that guides healthcare professionals toward specific clinical conditions and diagnostic hypotheses.

When characteristic autoantibody combinations are identified, the system supports result interpretation through associations with particular diseases and syndromes. This assists clinicians in decision-making and facilitates earlier referral for appropriate follow-up investigations and specialist consultations.

It is important to emphasize that the software guidance does not replace medical judgment but serves as a valuable tool for a more efficient analysis of laboratory data.

Broad Panel of Clinically Relevant Autoantibodies

The assay includes the determination of more than 40 specific autoantibodies associated with diseases such as:

• Systemic Lupus Erythematosus (SLE)
• Sjögren’s Syndrome
• Systemic Sclerosis (Scleroderma)
• Inflammatory Myopathies and Dermatomyositis
• Mixed Connective Tissue Disease (MCTD)
• Overlap Autoimmune Syndromes

Among the tested markers are Jo-1, PL-7, PL-12, EJ, OJ, Mi-2, MDA5, TIF1γ, NXP2, SAE, SRP54, HMGCR, Scl-70, CENP-A, CENP-B, Th/To, Fibrillarin, PM-Scl 75/100, Ro52, Ro60, La, SmB, SmD, RNP complexes, dsDNA, and other clinically significant antigens.

Autoantibodies and Their Clinical Associations

Different autoantibodies are associated with distinct clinical conditions:

• Anti-Jo-1, PL-7, and PL-12 are associated with antisynthetase syndrome and inflammatory myopathies.
• Anti-MDA5 may be associated with dermatomyositis and interstitial lung disease.
• Anti-Scl-70, CENP-A, and CENP-B support the diagnosis of systemic sclerosis.
• Anti-Ro52, Ro60, and La are important markers in Sjögren’s syndrome and other systemic autoimmune disorders.
• Anti-dsDNA, SmB, and SmD are highly relevant in the diagnosis of systemic lupus erythematosus.
• PM-Scl, Ku, and RNP antibodies may be associated with overlap syndromes and mixed connective tissue diseases.

When is the Test Recommended?

ANA PLUS Blot may be recommended in the presence of:

• Joint pain and stiffness
• Muscle weakness and muscle pain
• Raynaud’s phenomenon
• Dry eyes and mouth
• Skin manifestations suggestive of autoimmune disease
• Unexplained inflammatory symptoms
• Suspicion of connective tissue disease

Importance in Modern Diagnostics

Thanks to its broad autoantibody panel and intelligent software-assisted interpretation, ANA PLUS Blot supports a more accurate assessment of the patient's immunological profile. The system not only identifies the presence of autoantibodies but also guides specialists toward potential autoimmune conditions and diagnostic hypotheses, facilitating clinical decision-making and patient follow-up.

Sample required: Venous blood.